Filed pursuant to Rule 424(b)(3)
Registration No. 333-263603
PROSPECTUS
150,000 Shares of 9% Series A Convertible Preferred Stock
6,426,770 Shares of Class A Common Stock
This prospectus relates to the possible offer and resale, from time to time, by the selling stockholders identified in this prospectus (the “selling stockholders”) of up to (i) 150,000 shares of our 9% Series A Convertible Preferred Stock, par value $0.01 per share, which we refer to as the convertible preferred stock, and (ii) 6,426,770 shares of our Class A common stock, par value $0.01 per share, which may be issued upon conversion of the 150,000 shares of convertible preferred stock (collectively, the “securities”). We sold the shares of convertible preferred stock to the selling stockholders in connection with a private placement that was completed on September 29, 2021. The securities are being registered to fulfill our contractual obligations under a registration rights agreement entered into by us and the selling stockholders. We will not receive any of the proceeds from the sale of the securities by the selling stockholders.
The selling stockholders identified in this prospectus may offer the securities from time to time through public or private transactions at prevailing market prices or at privately negotiated prices, through a combination of these methods or any other method as provided in the applicable prospectus supplement.
We have agreed to pay certain expenses in connection with the registration of the securities. The selling stockholders will pay all selling commissions and stock transfer taxes, if any, in connection with the sale of the securities.
Our Class A common stock is listed on the NASDAQ Global Select Market (“Nasdaq”) under the symbol “DFH.” On March 11, 2022, the last sale price of our Class A common stock as reported on Nasdaq was $21.95.
Investing in our securities involves risks. You should read carefully this prospectus, the documents incorporated by reference in this prospectus and any prospectus supplement before you invest. See “Risk Factors” beginning on page 5 of this prospectus for information on certain risks related to the purchase of our securities.
Neither the Securities and Exchange Commission nor any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is March 23, 2022.